Evogene Ltd Stock TEL AVIV STOCK EXCHANGE
Equities
IL0011050551
Biotechnology & Medical Research
Sales 2024 * | 17M 6.39B | Sales 2025 * | 31.5M 11.84B | Capitalization | 32.16M 12.09B |
---|---|---|---|---|---|
Net income 2024 * | -20M -7.52B | Net income 2025 * | -17M -6.39B | EV / Sales 2024 * | 1.89 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.02 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.27% |
Latest transcript on Evogene Ltd
Managers | Title | Age | Since |
---|---|---|---|
Ofer Haviv
CEO | Chief Executive Officer | 58 | 01-12-31 |
Yaron Eldad
DFI | Director of Finance/CFO | 57 | 22-03-31 |
Mark Kapel
CTO | Chief Tech/Sci/R&D Officer | 48 | 04-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Falk
BRD | Director/Board Member | 79 | 21-11-16 |
Sarit Firon
CHM | Chairman | 58 | 16-08-10 |
Leon Recanati
BRD | Director/Board Member | 76 | 05-04-30 |
1st Jan change | Capi. | |
---|---|---|
-2.15% | 41.35B | |
+42.15% | 40.38B | |
+1.26% | 39.05B | |
-14.19% | 26.67B | |
+1.65% | 24.07B | |
-24.79% | 18.36B | |
-4.23% | 11.68B | |
+20.29% | 11.6B | |
+7.82% | 11.15B |